Erectile Dysfunction: Current Best Practices.
Erectile dysfunction is a health condition that many men face in the United States. Nurses are primed to help men break the stigma; assess, manage, and treat the underlying factors; and educate men an...
Protein-arginine N-methyltransferases : Questions médicales fréquentes
Questions fréquentes et termes MeSH associés
Diagnostic 5
#1
Comment diagnostiquer une dysfonction des N-méthyltransférases ?
Des tests génétiques et des analyses biochimiques peuvent être utilisés pour diagnostiquer.
#2
Quels tests sont utilisés pour évaluer l'activité enzymatique ?
Des tests enzymatiques spécifiques mesurent l'activité des N-méthyltransférases dans les échantillons.
#3
Y a-t-il des biomarqueurs associés à ces enzymes ?
Des biomarqueurs comme la méthylation de l'arginine peuvent indiquer une activité enzymatique.
#4
Quels symptômes peuvent indiquer un problème enzymatique ?
Des symptômes variés comme des troubles neurologiques ou immunitaires peuvent survenir.
#5
Comment les tests génétiques aident-ils au diagnostic ?
Ils identifient des mutations spécifiques dans les gènes codant pour ces enzymes.
Symptômes 5
#1
Quels sont les symptômes d'une carence en N-méthyltransférases ?
Les symptômes incluent fatigue, troubles cognitifs et anomalies immunitaires.
#2
Les troubles de l'humeur sont-ils liés à ces enzymes ?
Oui, des déséquilibres peuvent affecter l'humeur et contribuer à des troubles psychiatriques.
#3
Peut-on observer des symptômes neurologiques ?
Oui, des troubles neurologiques comme des convulsions peuvent être présents.
#4
Y a-t-il des symptômes spécifiques chez les enfants ?
Les enfants peuvent présenter des retards de développement et des troubles d'apprentissage.
#5
Comment les symptômes varient-ils selon l'âge ?
Les symptômes peuvent être plus prononcés chez les jeunes enfants et les personnes âgées.
Prévention 5
#1
Comment prévenir les troubles liés aux N-méthyltransférases ?
Une alimentation équilibrée et un mode de vie sain peuvent aider à prévenir ces troubles.
#2
Y a-t-il des mesures préventives spécifiques ?
Des dépistages précoces et des conseils génétiques peuvent être bénéfiques.
#3
L'éducation sur la santé est-elle importante ?
Oui, sensibiliser les patients et les familles peut aider à identifier les symptômes tôt.
#4
Les vaccinations jouent-elles un rôle préventif ?
Certaines vaccinations peuvent prévenir des infections qui aggravent les symptômes.
#5
Comment le suivi médical aide-t-il à la prévention ?
Un suivi régulier permet de surveiller l'état de santé et d'ajuster les traitements.
Traitements 5
#1
Quels traitements existent pour les dysfonctionnements enzymatiques ?
Les traitements peuvent inclure des suppléments nutritionnels et des thérapies ciblées.
#2
Les médicaments peuvent-ils aider à réguler ces enzymes ?
Oui, certains médicaments peuvent moduler l'activité des N-méthyltransférases.
#3
Y a-t-il des thérapies géniques disponibles ?
Des recherches sont en cours sur les thérapies géniques pour corriger les mutations.
#4
Comment la nutrition influence-t-elle le traitement ?
Une alimentation riche en nutriments peut soutenir la fonction enzymatique.
#5
Les traitements sont-ils personnalisés ?
Oui, les traitements peuvent être adaptés en fonction des besoins individuels du patient.
Complications 5
#1
Quelles complications peuvent survenir avec ces troubles ?
Des complications neurologiques, immunitaires et métaboliques peuvent se développer.
#2
Les troubles cardiovasculaires sont-ils possibles ?
Oui, des déséquilibres peuvent augmenter le risque de maladies cardiovasculaires.
#3
Comment les complications affectent-elles la qualité de vie ?
Elles peuvent entraîner des limitations fonctionnelles et des besoins de soins accrus.
#4
Y a-t-il des complications à long terme ?
Oui, des complications chroniques peuvent affecter la santé globale et le bien-être.
#5
Les complications peuvent-elles être évitées ?
Certaines complications peuvent être évitées par un traitement précoce et approprié.
Facteurs de risque 5
#1
Quels sont les facteurs de risque associés ?
Les facteurs incluent des antécédents familiaux, des mutations génétiques et des carences nutritionnelles.
#2
L'environnement joue-t-il un rôle ?
Oui, des facteurs environnementaux comme la pollution peuvent influencer la fonction enzymatique.
#3
Le mode de vie affecte-t-il le risque ?
Un mode de vie sédentaire et une mauvaise alimentation augmentent le risque de troubles.
#4
Les infections peuvent-elles être un facteur de risque ?
Certaines infections peuvent exacerber les symptômes et augmenter le risque de complications.
#5
Y a-t-il des groupes à risque spécifiques ?
Les personnes avec des antécédents familiaux ou des troubles métaboliques sont plus à risque.
Contenu validé par Dr Olivier Menir
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 23/03/2025
Contenu vérifié selon les dernières recommandations médicales
Auteurs principaux
Y George Zheng
4 publications dans cette catégorie
Affiliations :
- Department of Pharmaceutical and Biomedical Sciences, University of Georgia, Athens, GA 30602, United States. yzheng@uga.edu.
Publications dans "Protein-arginine N-methyltransferases" :
-
Protein arginine methyltransferase 6 is a novel substrate of protein arginine methyltransferase 1.
World journal of biological chemistry
-
The macromolecular complexes of histones affect protein arginine methyltransferase activities.
The Journal of biological chemistry 2021-09-06
-
Protein arginine methyltransferases: insights into the enzyme structure and mechanism at the atomic level.
Cellular and molecular life sciences : CMLS 2019-05-23
-
Hetero-oligomeric interaction as a new regulatory mechanism for protein arginine methyltransferases.
Biochemical Society transactions 2024-09-26
Adam Frankel
4 publications dans cette catégorie
Affiliations :
- Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia, Canada. Electronic address: adam.frankel@ubc.ca.
Publications dans "Protein-arginine N-methyltransferases" :
-
Protein arginine N-methyltransferase 2 plays a noncatalytic role in the histone methylation activity of PRMT1.
The Journal of biological chemistry 2023-10-19
-
The application of differential scanning fluorimetry in exploring bisubstrate binding to protein arginine N-methyltransferase 1.
Methods (San Diego, Calif.) 2019-11-11
-
Protein arginine N-methyltransferase activity determination with filter binding and phosphor screening (FBAPS) assay.
Analytical biochemistry 2022-06-13
-
Protein Arginine Methyltransferases in Cardiovascular and Neuronal Function.
Molecular neurobiology 2019-12-10
Alessandra Feoli
3 publications dans cette catégorie
Affiliations :
- Department of Pharmacy, Epigenetic Med Chem Lab, University of Salerno, via Giovanni Paolo II 132, Fisciano ,I-84084 SA Italy.
Publications dans "Protein-arginine N-methyltransferases" :
-
Identification of a Protein Arginine Methyltransferase 7 (PRMT7)/Protein Arginine Methyltransferase 9 (PRMT9) Inhibitor.
Journal of medicinal chemistry 2023-08-10
-
Turning Nonselective Inhibitors of Type I Protein Arginine Methyltransferases into Potent and Selective Inhibitors of Protein Arginine Methyltransferase 4 through a Deconstruction-Reconstruction and Fragment-Growing Approach.
Journal of medicinal chemistry 2022-04-28
-
Prodrug Approach to Exploit (S) Alanine as Arginine Mimic Moiety in the Development of Protein Arginine Methyltransferase 4 Inhibitors.
ChemMedChem 2024-05-16
Giulia Iannelli
3 publications dans cette catégorie
Affiliations :
- Department of Pharmacy, Epigenetic Med Chem Lab, University of Salerno, via Giovanni Paolo II 132, Fisciano ,I-84084 SA Italy.
- PhD Program in Drug Discovery and Development, University of Salerno, via Giovanni Paolo II 132, Fisciano ,I-84084 SA Italy.
Publications dans "Protein-arginine N-methyltransferases" :
-
Identification of a Protein Arginine Methyltransferase 7 (PRMT7)/Protein Arginine Methyltransferase 9 (PRMT9) Inhibitor.
Journal of medicinal chemistry 2023-08-10
-
Turning Nonselective Inhibitors of Type I Protein Arginine Methyltransferases into Potent and Selective Inhibitors of Protein Arginine Methyltransferase 4 through a Deconstruction-Reconstruction and Fragment-Growing Approach.
Journal of medicinal chemistry 2022-04-28
-
Prodrug Approach to Exploit (S) Alanine as Arginine Mimic Moiety in the Development of Protein Arginine Methyltransferase 4 Inhibitors.
ChemMedChem 2024-05-16
Alessandra Cipriano
3 publications dans cette catégorie
Affiliations :
- Department of Pharmacy, Epigenetic Med Chem Lab, University of Salerno, via Giovanni Paolo II 132, Fisciano ,I-84084 SA Italy.
Publications dans "Protein-arginine N-methyltransferases" :
-
Identification of a Protein Arginine Methyltransferase 7 (PRMT7)/Protein Arginine Methyltransferase 9 (PRMT9) Inhibitor.
Journal of medicinal chemistry 2023-08-10
-
Turning Nonselective Inhibitors of Type I Protein Arginine Methyltransferases into Potent and Selective Inhibitors of Protein Arginine Methyltransferase 4 through a Deconstruction-Reconstruction and Fragment-Growing Approach.
Journal of medicinal chemistry 2022-04-28
-
Prodrug Approach to Exploit (S) Alanine as Arginine Mimic Moiety in the Development of Protein Arginine Methyltransferase 4 Inhibitors.
ChemMedChem 2024-05-16
Ciro Milite
3 publications dans cette catégorie
Affiliations :
- Department of Pharmacy, Epigenetic Med Chem Lab, University of Salerno, via Giovanni Paolo II 132, Fisciano ,I-84084 SA Italy.
Publications dans "Protein-arginine N-methyltransferases" :
-
Identification of a Protein Arginine Methyltransferase 7 (PRMT7)/Protein Arginine Methyltransferase 9 (PRMT9) Inhibitor.
Journal of medicinal chemistry 2023-08-10
-
Turning Nonselective Inhibitors of Type I Protein Arginine Methyltransferases into Potent and Selective Inhibitors of Protein Arginine Methyltransferase 4 through a Deconstruction-Reconstruction and Fragment-Growing Approach.
Journal of medicinal chemistry 2022-04-28
-
Prodrug Approach to Exploit (S) Alanine as Arginine Mimic Moiety in the Development of Protein Arginine Methyltransferase 4 Inhibitors.
ChemMedChem 2024-05-16
Monica Viviano
3 publications dans cette catégorie
Affiliations :
- Department of Pharmacy, Epigenetic Med Chem Lab, University of Salerno, via Giovanni Paolo II 132, Fisciano ,I-84084 SA Italy.
Publications dans "Protein-arginine N-methyltransferases" :
-
Identification of a Protein Arginine Methyltransferase 7 (PRMT7)/Protein Arginine Methyltransferase 9 (PRMT9) Inhibitor.
Journal of medicinal chemistry 2023-08-10
-
Turning Nonselective Inhibitors of Type I Protein Arginine Methyltransferases into Potent and Selective Inhibitors of Protein Arginine Methyltransferase 4 through a Deconstruction-Reconstruction and Fragment-Growing Approach.
Journal of medicinal chemistry 2022-04-28
-
Prodrug Approach to Exploit (S) Alanine as Arginine Mimic Moiety in the Development of Protein Arginine Methyltransferase 4 Inhibitors.
ChemMedChem 2024-05-16
Sabrina Castellano
3 publications dans cette catégorie
Affiliations :
- Department of Pharmacy, Epigenetic Med Chem Lab, University of Salerno, via Giovanni Paolo II 132, Fisciano ,I-84084 SA Italy.
Publications dans "Protein-arginine N-methyltransferases" :
-
Identification of a Protein Arginine Methyltransferase 7 (PRMT7)/Protein Arginine Methyltransferase 9 (PRMT9) Inhibitor.
Journal of medicinal chemistry 2023-08-10
-
Turning Nonselective Inhibitors of Type I Protein Arginine Methyltransferases into Potent and Selective Inhibitors of Protein Arginine Methyltransferase 4 through a Deconstruction-Reconstruction and Fragment-Growing Approach.
Journal of medicinal chemistry 2022-04-28
-
Prodrug Approach to Exploit (S) Alanine as Arginine Mimic Moiety in the Development of Protein Arginine Methyltransferase 4 Inhibitors.
ChemMedChem 2024-05-16
Gianluca Sbardella
3 publications dans cette catégorie
Affiliations :
- Department of Pharmacy, Epigenetic Med Chem Lab, University of Salerno, via Giovanni Paolo II 132, Fisciano ,I-84084 SA Italy.
Publications dans "Protein-arginine N-methyltransferases" :
-
Identification of a Protein Arginine Methyltransferase 7 (PRMT7)/Protein Arginine Methyltransferase 9 (PRMT9) Inhibitor.
Journal of medicinal chemistry 2023-08-10
-
Turning Nonselective Inhibitors of Type I Protein Arginine Methyltransferases into Potent and Selective Inhibitors of Protein Arginine Methyltransferase 4 through a Deconstruction-Reconstruction and Fragment-Growing Approach.
Journal of medicinal chemistry 2022-04-28
-
Prodrug Approach to Exploit (S) Alanine as Arginine Mimic Moiety in the Development of Protein Arginine Methyltransferase 4 Inhibitors.
ChemMedChem 2024-05-16
Rong Huang
3 publications dans cette catégorie
Affiliations :
- Department of Medicinal Chemistry and Molecular Pharmacology, Center for Cancer Research, Institute for Drug Discovery, Purdue University, West Lafayette, IN 47907, United States.
Publications dans "Protein-arginine N-methyltransferases" :
-
Non-Histone Arginine Methylation by Protein Arginine Methyltransferases.
Current protein & peptide science
-
A Pan-Inhibitor for Protein Arginine Methyltransferase Family Enzymes.
Biomolecules 2021-06-08
-
Chemical Biology of Protein N-Terminal Methyltransferases.
Chembiochem : a European journal of chemical biology 2019-02-13
Shougang Zhuang
3 publications dans cette catégorie
Affiliations :
- Department of Medicine, Rhode Island Hospital and Alpert Medical School, Brown University, Providence, RI, U.S.A.
- Department of Nephrology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
Publications dans "Protein-arginine N-methyltransferases" :
-
The role of protein arginine methyltransferases in kidney diseases.
Clinical science (London, England : 1979)
-
Protein arginine methyltransferases in renal development, injury, repair, and fibrosis.
Frontiers in pharmacology 2023-02-03
-
The Role and Mechanism of Lysine Methyltransferase and Arginine Methyltransferase in Kidney Diseases.
Frontiers in pharmacology 2022-04-26
Jong-Sun Kang
3 publications dans cette catégorie
Affiliations :
- Department of Molecular Cell Biology, School of Medicine, Sungkyunkwan University, Suwon 16419, Korea.
- Single Cell Network Research Center, Sungkyunkwan University, Suwon 16419, Korea.
Publications dans "Protein-arginine N-methyltransferases" :
-
Protein Arginine Methyltransferases in Neuromuscular Function and Diseases.
Cells 2022-01-21
-
Role of Protein Arginine Methyltransferases and Inflammation in Muscle Pathophysiology.
Frontiers in physiology 2021-08-19
-
Protein Arginine Methyltransferases: Emerging Targets in Cardiovascular and Metabolic Disease.
Diabetes & metabolism journal 2024-07-24
Giuliana Sarno
2 publications dans cette catégorie
Affiliations :
- Department of Pharmacy, Epigenetic Med Chem Lab, University of Salerno, via Giovanni Paolo II 132, Fisciano ,I-84084 SA Italy.
- PhD Program in Drug Discovery and Development, University of Salerno, via Giovanni Paolo II 132, Fisciano ,I-84084 SA Italy.
Publications dans "Protein-arginine N-methyltransferases" :
-
Identification of a Protein Arginine Methyltransferase 7 (PRMT7)/Protein Arginine Methyltransferase 9 (PRMT9) Inhibitor.
Journal of medicinal chemistry 2023-08-10
-
Prodrug Approach to Exploit (S) Alanine as Arginine Mimic Moiety in the Development of Protein Arginine Methyltransferase 4 Inhibitors.
ChemMedChem 2024-05-16
Steven G Clarke
2 publications dans cette catégorie
Affiliations :
- Department of Chemistry and Biochemistry, and the Molecular Biology Institute, University of California, Los Angeles, California 90095, United States.
Publications dans "Protein-arginine N-methyltransferases" :
-
Identification of a Protein Arginine Methyltransferase 7 (PRMT7)/Protein Arginine Methyltransferase 9 (PRMT9) Inhibitor.
Journal of medicinal chemistry 2023-08-10
-
PRMT7 as a unique member of the protein arginine methyltransferase family: A review.
Archives of biochemistry and biophysics 2019-02-22
Yandong Lai
2 publications dans cette catégorie
Affiliations :
- Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Publications dans "Protein-arginine N-methyltransferases" :
Xiuying Li
2 publications dans cette catégorie
Affiliations :
- Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
- Veterans Affairs Pittsburgh Healthcare system, Pittsburgh, Pennsylvania, USA.
Publications dans "Protein-arginine N-methyltransferases" :
Tiao Li
2 publications dans cette catégorie
Affiliations :
- Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Publications dans "Protein-arginine N-methyltransferases" :
Toru Nyunoya
2 publications dans cette catégorie
Affiliations :
- Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
- Veterans Affairs Pittsburgh Healthcare system, Pittsburgh, Pennsylvania, USA.
Publications dans "Protein-arginine N-methyltransferases" :
Kong Chen
2 publications dans cette catégorie
Affiliations :
- Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Publications dans "Protein-arginine N-methyltransferases" :
Yingze Zhang
2 publications dans cette catégorie
Affiliations :
- Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Publications dans "Protein-arginine N-methyltransferases" :
Sources (10000 au total)
Chronic liver diseases and erectile dysfunction.
Chronic liver diseases (CLDs) are characterized by progressive necrosis of hepatocytes, which leads to liver fibrosis and cirrhosis, and ultimately liver dysfunction. The statistics of 2020 shows that...
A Review on Penile Doppler and Ultrasonography for Erectile Dysfunction.
Herein, we seek to review the clinical applications of penile duplex Doppler ultrasound (PDDU) in sexual medicine practices and discuss the indications, protocols, advantages, and limitations of this ... PDDU has become a key diagnostic tool in the clinical evaluation of both erectile dysfunction (ED) and Peyronie's disease (PD). With the assistance of intracavernosal injections such as alprostadil, c...
Conservative Non-surgical Options for Erectile Dysfunction.
This study aimed to review recent evidence on conservative non-surgical options for erectile dysfunction (ED) in men. A narrative review of the literature was performed. A comprehensive search in the ... We found a multitude of different treatment modalities for ED. We must take into account the type of patient, their comorbidities, the origin of their ED, and its severity in order to reproduce effect...
Current status of intracavernosal injection therapy in erectile dysfunction.
Erectile dysfunction (ED) is defined as the inability to attain and/or maintain a penile erection. The first introduction of intracavernosal injection (ICI) for the treatment of erectile failure was i... We performed a literature review from 1977-2022, using PubMed and the current AUA and EAU guidelines to discuss the current state of ICI for the treatment of ED.... Although other oral agents are considered first line for the treatment of ED, the current guidelines and literature demonstrate that ICI is a safe and effective option for patients; however, careful p...
Is Reddit a reliable source for information on erectile dysfunction treatment?
Patients may turn to social media websites, such as Reddit, for information on erectile dysfunction prior to seeking care from a physician. We sought to identify, characterize, and assess the quality ...
Talking about sex: erectile dysfunction in the oncology patient.
Cancer-related diagnosis and treatments can profoundly affect every aspect of an individual's life. The negative impact on the sexual sphere can manifest with onset or worsening of the most frequent m...
Management of male erectile dysfunction: From the past to the future.
Erectile dysfunction is a common disease of the male reproductive system, which seriously affects the life quality of patients and their partners. At present, erectile dysfunction is considered as a s...
An Electrophysiological Technique to Accurately Diagnose and Treat Erectile Dysfunction.
Erectile dysfunction (ED) is a common disease in males. In the past, the first-line treatment of ED was mainly noninvasive-psychotherapy and oral phosphodiesterase 5 (PDE5) inhibitors. Oral PDE5 inhib...
Relationship Between Age, Comorbidity, and the Prevalence of Erectile Dysfunction.
Erectile dysfunction (ED) increases with age. Remarkably, the relationship between age and the risk of ED has only been described in crude categories, such as risk for men aged 50-59 yr, without takin... To understand how the risk of patient-reported ED varies according to age and comorbidity status.... This cross-sectional study included a cohort of 17 250 patients with prostate cancer who completed the International Index of Erectile Function erectile function domain (IIEF-EF) questionnaire before ... We created a logistic regression model to predict the probability of ED using age and comorbidities such as cardiovascular disease, diabetes, and hypertension as predictors. We used age as a nonlinear... The prevalence of patient-reported ED among men without any comorbidities increased from 10% to 79% from the age of 40 and 80 yr. The risk of ED increased sharply with comorbidity: the probability of ... Our results allow us to better understand how the risk of ED changes with age and comorbidities. Further research should evaluate the impact of other risk factors not considered in the present study a... Our study shows how the probability of erectile dysfunction (ED) changes with increasing age, analyzed alone and when taking into account the presence of other risk factors for this condition (eg, dia...